首页> 外文期刊>American journal of therapeutics >Screening for nephropathy and antiangiotensin use among diabetic patients in an academic community medical center.
【24h】

Screening for nephropathy and antiangiotensin use among diabetic patients in an academic community medical center.

机译:在学术社区医疗中心对糖尿病患者的肾病和抗血管紧张素的使用进行筛查。

获取原文
获取原文并翻译 | 示例
           

摘要

The American Diabetes Association recommends routine screening for albuminuria to detect early nephropathy in all patients with diabetes mellitus. If nephropathy is identified, treatment with an antiangiotensin agent decreases progression and improves renal outcomes. Concordance with guidelines for nephropathy screening and antiangiotensin therapy among diabetic patients in a primary care setting of an academic community medical center was evaluated. Medical charts of adult patients with diabetes mellitus from February 2000 through January 2003 were retrospectively reviewed. In part 1 of the study, whether patients were screened for nephropathy at least once was recorded. In part 2 of the study, antiangiotensin prescribing was assessed in all patients and in subgroups stratified by screening. In both parts of the study, patient characteristics and comorbidities were assessed using multivariate analysis to determine their impact on the odds that a patient was screened and that antiangiotensin therapy was prescribed. Among the 329 patients included, 182 patients (55.3%) were screened for nephropathy. Patients who were screened were younger (OR=0.83 for 10-year increase, 95% CI: 0.69-0.99), less likely to have congestive heart failure (OR=0.42, 95% CI: 0.20-0.90), and more likely to be cared for by a resident physician directly supervised by an attending physician (OR=3.03; 95% CI: 1.82-5.03). A total of 215 patients (65.3%) were prescribed antiangiotensin therapy. Hypertension was a predictor of antiangiotensin therapy among all patients who were screened (OR=10.34, 95% CI: 4.45-24.01), those who were screened and negative (OR=15.46, 95% CI: 5.56-42.98), and those who were not screened (OR=10.79, 95% CI: 4.39-26.52). Among patients screened for nephropathy, coronary artery disease (OR=3.01, 95% CI: 1.05-8.63), and the presence of proteinuria (OR=4.26, 95% CI: 1.61-11.24) were predictors of antiangiotensin use. This study found that the likelihood of screening for nephropathy among diabetic patients was inversely associated with a diagnosis of congestive heart failure and increasing age. Conversely, care by a resident physician directly supervised by an attending physician increased the odds that patients would be screened. A diagnosis of hypertension and the presence of albuminuria were each associated with increased use of an antiangiotensin agent.
机译:美国糖尿病协会建议常规筛查蛋白尿,以发现所有糖尿病患者的早期肾病。如果识别出肾病,则用抗血管紧张素药治疗可降低进展并改善肾结局。在学术社区医疗中心的初级保健机构中,对糖尿病患者的肾病筛查和抗血管紧张素治疗的指南进行了评估。回顾性分析了2000年2月至2003年1月成年糖尿病患者的病历。在研究的第1部分中,记录了患者是否至少筛查过一次肾病。在研究的第二部分中,对所有患者和通过筛选分层的亚组评估了抗血管紧张素处方。在研究的两个部分中,使用多变量分析评估了患者的特征和合并症,以确定其对筛查患者和开具抗血管紧张素疗法的几率的影响。在329名患者中,有182名(55.3%)接受了肾病筛查。被筛查的患者年龄较小(10年增加OR = 0.83,95%CI:0.69-0.99),充血性心力衰竭的可能性较小(OR = 0.42,95%CI:0.20-0.90),并且更有可能由直接由主治医师监督的住院医师进行护理(OR = 3.03; 95%CI:1.82-5.03)。共有215例患者(65.3%)被处方抗血管紧张素治疗。在所有筛查的患者中(OR = 10.34,95%CI:4.45-24.01),筛查阴性的患者(OR = 15.46,95%CI:5.56-42.98),高血压是抗血管紧张素治疗的预测指标。未被筛选(OR = 10.79,95%CI:4.39-26.52)。在接受肾病筛查的患者中,冠状动脉疾病(OR = 3.01,95%CI:1.05-8.63)和蛋白尿的存在(OR = 4.26,95%CI:1.61-11.24)是抗血管紧张素使用的预测指标。这项研究发现,在糖尿病患者中筛查肾病的可能性与充血性心力衰竭和年龄增长的诊断呈负相关。相反,由住院医师直接在主治医师的监督下进行护理会增加筛查患者的几率。高血压的诊断和白蛋白尿的存在均与抗血管紧张素药的使用增加有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号